Intellia Signs a License and Collaboration Agreement with ONK to Advance Allogeneic CRISPR-Edited NK Cell Therapies for Cancer
Shots:
- Intellia to receive ~$184M/product in development & commercial milestone along with royalties & gets an option to co-develop & co-commercialize ~2 products with commercialization rights in the US
- ONK gets a non-exclusive license to Intellia’s ex vivo CRISPR/Cas9-based genome editing platform & LNP-based delivery technologies along with an exclusive right to gRNAs for ~5 allogeneic CRISPR-edited NK cell therapies
- The collaboration will combine Intellia’s genome editing platform with ONK’s optimized NK cell therapy platform to develop NK cell-based cancer immunotherapy. ONK will lead the research, clinical development & commercialization of engineered NK cell therapies
Ref: Globe Newswire | Image: Intellia
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com